Clinical Trial Update: Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial is evaluating a once-weekly formulation of brexpiprazole for acute schizophrenia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Brexpiprazole (Rexulti) (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Acute Schizophrenia | Phase 3 | Status: RECRUITING